Clinical Trials Directory

Trials / Completed

CompletedNCT00862875

Levemir-Body Composition and Energy Metabolism

Effects of Basal Insulin Analogue Detemir on Body Composition, Epicardial Fat and Energy Metabolism

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
42 (actual)
Sponsor
Institut de Recherches Cliniques de Montreal · Academic / Other
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Not accepted

Summary

The objectives is to compare the changes in body composition (primary objective), diabetes parameters, energy expenditure and energy intake between Insulin detemir (Levemir® - Novolin® 4 pen) and insulin glargine (Lantus® - Solostar®) both in combination with Metformin and insulin secretagogues (SU) between baseline and after 6 months of insulin therapy in 80 type 2 diabetic patients failing on oral diabetic agents .

Conditions

Interventions

TypeNameDescription
DRUGDetemir or GlargineInitial dose of 10 units of insulin at bedtime. The insulin dose will be increase by 1 unit per day until fasting plasma glucose (FPG) levels are 5.0 mmol/L.

Timeline

Start date
2009-03-01
Primary completion
2014-04-01
First posted
2009-03-17
Last updated
2014-05-07

Locations

1 site across 1 country: Canada

Source: ClinicalTrials.gov record NCT00862875. Inclusion in this directory is not an endorsement.

Levemir-Body Composition and Energy Metabolism (NCT00862875) · Clinical Trials Directory